Quest Diagnostics (DGX) Tops Q2 EPS by 5c; Maintains FY Adjusted EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Jefferies Raises Price Target on Quest Diagnostics (DGX) to $86 Following 2Q Earnings Report
July 22, 2016 8:39 AM EDTJefferies reiterated a Hold rating on Quest Diagnostics (NYSE: DGX), and raised the price target to $86.00 (from $75.00), following the company's 2Q earnings report. DGX posted its 3rd consecutive quarter of positive organic volume growth. However, pricing remains under pressure.
Analyst Brian Tanquilut... More
Quest Diagnostics (DGX) PT, Estimates Raised at Evercore ISI Amid Solid Q2
July 21, 2016 12:00 PM EDTEvercore ISI analyst Ross Muken raised estimates and his price target on Quest Diagnostics (NYSE: DGX) to $89.50 (from $78.50) but maintained a Hold rating following results.
The firm raised FY 2016 EPS from $5.10 to $5.15, FY 2017 EPS from $5.55 to $5.60 and FY 2018 EPS from $5.95 to $6.15.
Muken commented, "Quests turnaround momentum continues as volumes have stabilized in the LSD, with a consistent price headwind... More
